There is increasing evidence that a degenerative neurological disease known as 'tropical ataxia' or 'tropical ataxic neuropathy' in Nigeria may be caused, at least partly, by the consumption of cassava, the staple diet of large numbers of people living in tropical and sub-tropical areas.
A recent epidemiological study of the disease in Western Nigeria has shown that the prevalence of the syndrome varies with the amount of cassava eaten (Osuntokun, Monekosso, and Wilson, 1969) but it is also recognized that there is co-existing malnourishment in other respects, notably in the intake of the sulphur-containing amino acids, and perhaps of riboflavine.
It is well known that the tuber of cassava (Manioc utilissima) contains large amounts of the cyanogenetic glycoside linamarin in its outer integument and, although the indigenous methods of food preparation eliminate most of this compound from the edible product, significant quantities of cyanogenetic material, and perhaps free cyanide, persist and are ingested.
It has, therefore, been suggested that this degenerative neurological disease may represent a form of chronic cyanide toxicity which may be related to Leber's disease (Wilson, 1963 (Wilson, , 1965 , subacute combined degeneration of the cord (Wilson and Langman, 1966) , and tobacco amblyopia (Smith, 1961 an important detoxication product of cyanide, have been found in the serum of patients with tropical ataxia compared with that of control individuals (Monekosso and Wilson, 1966; Osuntokun, 1968; Osuntokun, Monekosso, and Wilson, 1969) . Changes in the distribution of cyanide-displaceable proteinbound vitamin B12 in plasma have also been demonstrated (Monekosso and Wilson, 1966; Osuntokun, 1968; Osuntokun et al., 1969) , and the findings are consistent with the suggestion that cyanide or cyanogen ingestion in patients is excessive. Since hydroxocobalamin has a strong affinity for cyanide in vitro, and has a demonstrable protective effect in acute cyanide poisoning in vivo, it was decided to conduct a therapeutic trial of this agent in a group of Nigerian patients suffering from the disease. Riboflavine was also included in the trial in view of the suggestion that deficiency of this vitamin may be a contributory factor.
PATIENTS
The 80 patients treated all showed the clinical features of the ataxic neuropathy as previously described (Osuntokun, 1968 (Osuntokun, , 1969 Clinical assessment was completed before and after the trial according to a scheme modified from Alexander (1951) in which neurological signs and symptoms were scored numerically. Improvement or deterioration during the trial was represented by a reduction or an increase in the score respectively. The patients' practical disabilities were also assessed at the beginning and at the end of the trial by the method suggested by Miller, Newell, and Ridley (1961) .
Plasma thiocyanate and cyanide concentrations were estimated by the method of Aldridge (1945) , cyanide being separated from thiocyanate by an aeration technique described by Boxer and Rickards (1951) . Serum vitamin B12 concentrations were estimated in duplicate, on aliquots of sera with and without the addition of cyanide to the buffer used in extracting vitamin B12 bound to serum proteins, as described by Smith (1961) and Wilson and Matthews (1966) . It has been suggested that differences in 'extractability' thus demonstrated are the consequence of cyanide exposure. Assessment by disability scale added no useful information to that obtained from the neurological examination scores, and therefore in Table 3 *The omission of one figure of +210-0y% reduces this figure to + 1-6y%.
Controlled trial of hydroxocobalamin and riboflavine in Nigerian ataxic neuropathy culating the percentage change in total neurological score for each patient-(for example, initial score = 50, final score = 60, therefore percentage change = 20% in deterioration). Table 3 shows the mean percentage change in neurological scores, but in making statistical comparisons a non-parametric ranking test (Mann Whitney U test) was applied: the differences found between hydroxocobalamin and control, and riboflavine and control were statistically insignificant (P = 0 1 and P = 0-4 respectively).
To ensure that minor improvements in individuals with less severe neurological disease were not being masked by poor results in those with severe disease, the findings were considered separately for those with less severe disease (initial score less than 100) and severe disease (initial score 100 or more). The results, which are given in Table 4 , show no evidence of such a masking effect. Separate consideration of the results obtained in the irregular attenders at the Clinic did not suggest that their neurological changes differed in any important respect from those found in the remainder. At the end of the trial patients were asked whether they considered that they had benefited from the treatment and Table 5 shows the results of these subjective assessments. A greater proportion of individuals treated with hydroxocobalamin thought that they had benefited from treatment than did those given riboflavine or the control preparation but the difference was not statistically significant (X2 = 2-20 P = 0 34) in comparing all improved with all 'no change' or 'worse'. Plasma thiocyanate concentrations were determined at the start of the trial and at the mid-point and are shown in Table 6 for patients in each of the three treatment groups. The concentrations tended to fall irrespective of the treatment given and there were no significant differences between them. Plasma cyanide concentrations could be determined in only 28 of the patients at the start of the trial because of the problems posed by making the estimations in the District Centre. There was a correlation between plasma thiocyanate and cyanide concentration (r = 0-60P < 0-001) with a tendency for increasing variability as both values rose. 10-7 ± 09 90 ± 07 12-0 ± 1-0 10-6 ± 0-9 99 ± 0-6 7-9 ± 07 26 21 25
DISCUSSION
The present study leaves no doubt that, under the conditions of the trial, there was no significant objective benefit attributable to treatment with either hydroxocobalamin or riboflavine, although, as judged subjectively, there was some evidence favouring hydroxocobalamin.
The organization of such a trial as this presented formidable practical difficulties in a rural Nigerian setting, but we are satisfied that the double-blind scheme adopted for the trial was effective and that the patients allocated the three different treatments were comparable with each other.
The biochemical features of the patients were similar to those seen in other series (Monekosso and Wilson, 1966; Osuntokun, 1968) and almost certainly reflect the high cyanide or cyanogen exposure experienced by this population, which consumes large quantities of cassava. As in other series, the high serum levels of vitamin B12 remain unexplained. The slight fall in mean plasma thiocyanate concentrations in the three treatment groups seen during the trial may be a reflection of the longitudinal variation of cyanide or cyanogen intake according B. 0. Osuntokun, M. J. S. Langman, J. Wilson, and A. Akadetoyinbo to the season rather than of any non-specific treatment effects.
Previous therapeutic trials using B vitamin preparations have yielded conflicting results. Spillane (1947) was disappointed with the results of thiamine administration in wartime cases of tropical neuropathy that he studied, and Pallister (1940) and McLaren (1960) noted the absence of improvement with the administration of vitamin B complex in their cases. Others (Wright, 1928; Nicholls, 1935) claimed some improvement with yeast or Marmite, and assumed that this was due to the content of B vitamins. However, other nutritional factors present-for instance, cystine-may have been effective.
The same may be true of the trial reported by Monekosso, Annan, and Ashby (1964) in which controls as well as patients treated with thiamine improved, for both groups were hospital in-patients and therefore probably benefited from non-specific dietary improvements. Clark (1936) claimed that Oluwole successfully treated Nigerian children with tropical amblyopia by reducing the amount of cassava in the diet. These observations have not been deliberately reproduced subsequently, but Moore (1937) treated a small group of Nigerians suffering from the amblyopic syndrome with intravenous thiosulphate solution, as an antidote to cyanogen derived from cassava, without apparent benefit.
The present trial was designed to test the hypothesis of cyanogen intoxication by including further hydroxocobalamin as a potent antagonist of cyanide. The lack of therapeutic success does not necessarily invalidate the hypothesis, for the absence of clearcut improvement could be due among other things to inadequate dosage, both of hydroxocobalamin and of riboflavine.
While hydroxocobalamin binds cyanide very quickly, weight for weight it is relatively inefficient, a reflection of its very high molecular weight. In addition, it must be emphasized that the patients in this trial continued to subsist on their normal diet with its inevitably high cyanogen content. It is improbable that well-established dietary habits can be substantially modified in this community but a further trial using much higher doses of hydroxocobalamin, for comparison with large doses of vitamin B complex and cystine, as a further cyanide detoxicant, is now in progress because it is not considered that this initial negative therapeutic result invalidates the hypothesis of cyanide intoxication.
